Medtronic (NYSE:MDT) Stock Rating Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of Medtronic (NYSE:MDT – Free Report) from a buy rating to a hold rating in a research note issued to investors on Monday,Wall Street Zen reports.

Other equities analysts have also issued research reports about the stock. TD Cowen restated a “buy” rating and set a $110.00 target price on shares of Medtronic in a report on Wednesday, September 30th. Wells Fargo & Company raised their target price on Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a report on Wednesday, September 2nd. Barclays raised Medtronic to a “hold” rating in a research report on Wednesday, October 7th. Mizuho set a $115.00 price target on Medtronic in a report on Wednesday, September 2nd. Finally, Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research report on Wednesday, October 14th. Eighteen equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $102.88.

Get Our Latest Analysis on MDT

Medtronic Trading Up 0.1%

Shares of MDT opened at $102.92 on Monday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. Medtronic has a 1-year low of $73.31 and a 1-year high of $106.33. The stock has a market cap of $131.65 billion, a price-to-earnings ratio of 25.35, a price-to-earnings-growth ratio of 2.36 and a beta of 0.56. The firm has a 50 day simple moving average of $93.89 and a 200-day simple moving average of $88.49.

Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The company had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. During the same quarter last year, the business posted $1.26 earnings per share. Medtronic’s revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities analysts forecast that Medtronic will post 5.98 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 16th. Stockholders of record on Friday, September 25th were issued a dividend of $0.72 per share. The ex-dividend date of this dividend was Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 2.8%. Medtronic’s payout ratio is 70.94%.

Insider Activity at Medtronic

In other Medtronic news, CEO Geoffrey Martha sold 50,000 shares of the business’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the completion of the transaction, the chief executive officer owned 277,866 shares in the company, valued at approximately $26,397,270. The trade was a 15.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Marinaro sold 10,420 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total value of $1,000,320.00. Following the sale, the executive vice president directly owned 105,916 shares in the company, valued at approximately $10,167,936. The trade was a 8.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 61,903 shares of company stock worth $5,889,203 in the last three months. 0.27% of the stock is owned by company insiders.

Institutional Trading of Medtronic

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in shares of Medtronic by 0.7% during the second quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company’s stock worth $8,919,846,000 after purchasing an additional 838,220 shares during the period. State Street Corp boosted its stake in Medtronic by 4.1% during the 3rd quarter. State Street Corp now owns 65,987,354 shares of the medical technology company’s stock valued at $5,741,306,000 after purchasing an additional 2,588,039 shares during the period. Bank of America Corp DE grew its stake in shares of Medtronic by 5.4% in the first quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company’s stock worth $2,254,200,000 after acquiring an additional 1,343,220 shares during the last quarter. First Eagle Investment Management LLC increased its position in Medtronic by 1.2% during the third quarter. First Eagle Investment Management LLC now owns 13,948,408 shares of the medical technology company’s stock worth $1,203,608,000 after acquiring an additional 164,425 shares during the period. Finally, WCM Investment Management LLC bought a new position in Medtronic during the first quarter worth $965,922,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Latest Medtronic News

Investors following MDT have been watching these news items:

  • Positive Sentiment: Medtronic plans to acquire privately held Contego Medical for $380 million. Contego develops treatments for carotid artery disease and peripheral thrombectomy; the deal would expand Medtronic’s vascular portfolio and build on an existing U.S. distribution partnership. Medtronic to buy Contego Medical for $380M
  • Negative Sentiment: Wall Street Zen lowered its rating on Medtronic shares, a potentially negative sentiment signal. The article listing does not specify the revised rating or rationale. Medtronic Stock Rating Lowered by Wall Street Zen

Medtronic Company Profile

(Get Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Featured Stories

Analyst Recommendations for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.